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mize selection bias. Patients in both groups were required to be at least age 18 years, 
with continuous medical and pharmacy benefits 1 year before, and 1 year after the 
index date. One-to-one propensity score matching (PSM) was used to compare health 
care costs and utilizations during the follow-up period between the menopausal and 
the comparison groups, and were adjusted for baseline demographic and clinical 
characteristics. Results: After risk adjustment by PSM, a total of 67,740 patients 
in each cohort were matched. More menopausal patients had inpatient admissions 
(15.18% vs. 11.89%, p< 0.0001) and other service (99.98% vs. 90.29%, p< 0.0001) and 
pharmacy visits (86.55% vs. 71.23%, p< 0.0001) compared to those without menopause. 
Menopausal patients also incurred significantly higher other service visit ($11,215 vs. 
$8,812, p< 0.0001) and pharmacy costs ($2,448 vs. $1,878, p< 0.0001) than comparison 
patients. ConClusions: In the U.S. Medicaid program, menopausal patients had 
higher health care utilization and incurred higher costs than those without meno-
pause, highlighting the economic burden of the disease.
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objeCtives: Infantile Hemangioma (IH) is one of the most common childhood 
benign tumours. Recent studies have demonstrated the success of propranolol for 
involution of IH and the higher clinically effective and safe compared with corti-
costeroids. The purpose of this study is to estimate the cost-utility of propranolol, 
a new medicinal product authorized for this specific paediatric indication (3.75 mg/
mL, oral solution) versus corticosteroids (5.00 mg, tablets), used in clinical practice 
in absence of other authorised therapies of proliferating IH requiring systemic treat-
ment. Methods: A life-time (30 years) mixed decision tree and Markov model 
has been developed to describe the pathway of infants with IH and to assess costs 
and outcomes (Quality-Adjusted Life Years – QALYs – gained) from the perspec-
tive of the Italian National Health Service (INHS). Clinical inputs derive from the 
manufacturer’s pivotal trial and literature review, validated by key clinicians in Italy. 
The economic evaluation considers direct medical costs associated with IH (drug 
acquisition, hospital admissions and outpatient visits) derived from public sources. 
The atopic dermatitis as a proxy for IH utilities, the Infants Dermatitis Quality of 
Life Index and the Children’s Dermatology Life Quality Index were used to estimate 
quality of life. Probabilistic sensitivity analyses (PSA) were performed to investigate 
model parameter uncertainties. Costs and health benefits have been discounted at 
an annual rate of 3.00%. Results: The cumulative costs are € 2,399.32 and € 1,859.68 
while cumulative QALYs are 19.11 and 18.95 for propranolol and for corticoster-
oids respectively, corresponding to an ICUR of € 3,372.75/QALY. PSA results suggest 
that 94.60% of the 1000 iterations fall within a € 30,000 cost-effectiveness threshold 
considered acceptable for a marginal unit of effectiveness. ConClusions: The 
propranolol (3.75 mg/mL, oral solution for paediatric use) for the treatment of pro-
liferating IH can be considered cost-effective compared to corstisteroids (5.00 mg, 
tablets) in the INHS perspective.
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objeCtives: The aim of this study was to assess the cost-effectiveness of HZ vac-
cination compared to no vaccination strategy which only involves the treatment of 
patients affected by HZ, within the Italian context. Methods: The natural history 
of HZ and PHN was mapped through a Markov model with lifetime horizon and 
cycles lasting one month. Both third party payer (the Italian National Health Service) 
and societal perspectives were adopted. Costs and Effectiveness data was derived 
from literature and discounted by 3.5%. Model results are expressed in terms of 
incremental cost-effectiveness ratio (ICER). Both deterministic and probabilistic 
sensitivity analyses were performed to appraise the effect of parameters’ variation 
on model results. Results: A population of patients with HZ aged between 60 and 
79 years was hypothesized. The ICER of the vaccination equaled € 12,155 per QALY 
under the NHS perspective and € 11,118 per QALY under the societal perspective. 
Moreover, under NHS perspective the cost per HZ-episode avoided and the cost per 
PHN-episode avoided amounted to € 1,098 and € 8,742 respectively. Considering a 
cost-effectiveness threshold of € 30,000/QALY, the probabilistic sensitivity analysis 
showed that vaccination is cost-effective regardless of the perspective adopted, in 
99% of simulations. ConClusions: Results showed that a vaccination program 
against herpes zoster and post-herpetic neuralgia is cost-effective in Italian patients 
aged between 60 and 79 years.
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objeCtives: The objective of this study was to estimate the incremental cost-
effectiveness ratio (ICER) of a medication review with follow-up (MRF) service for 
older people with polypharmacy in community pharmacies against the alternative 
of receiving usual dispensing. Methods: The study was designed as a longitudi-
nal cluster randomized trial carried out over six months of follow-up. The target 
was to assess the incremental cost effectiveness of using serum CysC (sCysC), urine 
NGAL (uNGAL) and urine L-FABP (uL-FABP) for the diagnosis of AKI in children 
after cardiac surgery compared with current diagnostic method (monitoring of sCr 
level). Methods: We developed a decision analytical model to estimate quality-
adjusted life years (QALY), lifetime costs and incremental cost-effectiveness of dif-
ferent biomarker-based diagnostic strategies which can be used in clinical practice 
compared to current strategy. This model simulates detection of AKI, its progression 
to chronic kidney disease (CKD) and CKD treatment in cohort of patients younger 
than 18 years. Results: The cost-effectiveness ratios were between $1485/QALY for 
sCr and $3579/QALY for uNGAL. uNGAL and sCys C strategies yielded higher costs 
and lower effectiveness (ie. dominated) compared to uL-FABP strategy. uL-FABP 
added 1.43 QALY compared to current diagnostic method at an additional cost of 
$8521.87. ICER for uL-FABP compared to sCr was $5959.35/QALY. Probabilistic sensi-
tivity analyses indicated that the uL-FABP strategy was cost-effective for all 10.000 
patient simulations at specified $50000/QALY threshold. ConClusions: Our results 
suggest that the use of uL-FABP is likely to represent an economically advantageous 
strategy for early AKI diagnosis in children after cardiac surgery. However, we need 
rapid screening uL-FABP test to ensure timely and efficient AKI treatment.
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objeCtives: Endometriosis is a disease with social and economic impact. We anal-
yses the clinical and pharmaco-economical efficacy of the treatment of genital 
endometriosis. Methods: This open-label prospective comparative research was 
performed in 2012-2013 on Center of Endometriosis of Astana. Results of treat-
ment taken from 180 female patients with endometriosis aged 19-35 years old were 
included into the study. All of them were divided on three groups depending on the 
methods of therapy. 1st group have a endo-surgery treatment (60 patient), 2nd group 
(60 patient) - only hormonal therapy (Dienogest 2 mg per day for 6 months) and 3rd 
group - combined therapy (after endo-surgery taken the Dienogest 2 mg per day 
for 6 months). For the calculation of cost/effectiveness index we included all of the 
direct medical expenses. Results: In the first group efficacy index is 66,7%, in the 
second group – 70,0% and in the third group – 91,7%. Index cost/effectiveness for 
endo-surgery is 143 298 KT (1$= 182KT), cost/effectiveness for hormonal therapy 
is 92 428 KT and cost/effectiveness for combined methods is 115 718 KT. Surgical 
treatment has the low efficiency of the high costs compared with other therapies. 
The indicator of cost/effectiveness of the combined therapy is higher than in the 
hormonal treatment: higher efficiency cost in additional costs. For the objectifica-
tion of this fact calculated Incremental Index per patient: 186 500 - 107 833 / 92.0 
- 70.0 = 182 KT. So, the increase of one percent of effectiveness combined therapy 
compare to hormonal therapy reflects additional cost, not more than 182 KT per 
patient. ConClusions: Hormonal therapy resulted as the cost-saving therapy of 
genital endometriosis in young women. The higher efficiency of treatment of endo-
metriosis are needed additional expenses.
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objeCtives: Most elderly prefer to grow old in the community within a famil-
iar environment, instead of moving to a nursing home. Preventive home visits 
based on multidimensional geriatric assessment can be one strategy to support 
this preference and might additionally reduce health care costs, due to the avoid-
ance of costly nursing home admissions. The purpose of this study was to ana-
lyse the cost-effectiveness of preventive home visits from a societal perspective in 
Germany. Methods: This study is part of a multi-centre, non-blinded, randomised 
controlled trial. Participants were older than 80 years and living at home. Three 
home visits were conducted to identify self-care deficits and risk factors, to pre-
sent recommendations and to implement solutions. The control group received 
usual care. A cost-utility analysis using QALY based on the EQ-5D was performed. 
A cost-effectiveness acceptability curve controlled for confounding variables was 
constructed. A sensitivity analysis to control for the influence of the mode of QALY 
calculation was performed. Results: 278 individuals were included in the analy-
sis. Mean total cost (+874 EUR) and number of QALY (+0.0014) were higher in the 
usual care group, but differences were not significant. The probability for cost-
effectiveness of preventive home visits increased from 6% (Willingness-to-pay: 
0 € / QALY) 30% (Willingness-to-pay: 250.000 € / QALY). The results were robust to 
the mode of QALY calculation. The probability of cost-effectiveness did not exceed 
30%. ConClusions: We found convincing evidence that the evaluated preventive 
home visits programme is not cost-effective.
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objeCtives: To evaluate the economic burden of menopausal women enrolled in the 
U.S. Medicaid program. Methods: Menopausal women (International Classification 
of Disease, 9thRevision, Clinical Modification [ICD-9-CM] diagnosis code 627) were 
identified using U.S. Medicaid data from 01JAN2008 through 31DEC2010. The initial 
diagnosis date was designated as the index date. A separate group of patients without 
a menopause diagnosis but of the same age, race, and gender was identified, matched 
and designated as the comparison group. A random index date was chosen to mini-
